{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:52:25Z","timestamp":1774929145428,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>CD22 single and CD19\/CD22 bispecific targeted chimeric antigen receptor T (CAR-T) cell therapy are promising immunotherapy modalities for the treatment of hematologic malignancies. The aim of this study was to assess the efficacy and safety of CD22 and CD19\/CD22 targeted CAR-T cell therapy by summarizing the existing evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic databases including PubMed, Embase, and Scopus were comprehensively searched from inception up to November 30, 2022. Pooled response rates and minimal residual disease (MRD) negative response rates, cytokine release syndrome (CRS) rates and neurotoxicity rates were calculated. Subgroup analysis was performed based on the type of immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten clinical studies including 194 patients with hematologic malignancies were included after a systematical screening of literature. The pooled complete response (CR) rates of CD22 and CD19\/CD22 CAR-T cell therapy for relapsed or refractory B-cell lymphoblastic leukemia (B-ALL) were 0.75 (95% CI: 0.60 - 0.88) and 0.87 (95% CI: 0.76 - 0.96). The overall MRD negative response rates of CD22 and CD19\/CD22 CAR-T were 0.54 (95% CI: 0.42 - 0.66) and 0.91 (95% CI: 0.47 - 0.88). Pooled CRS rates of CD22 targeted and CD19\/CD22 targeted immunotherapy were 0.92 (95% CI: 0.82 - 0.98) and 0.94 (95% CI: 0.82 - 1.00), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both CD22 and CD19\/CD22 CAR-T immunotherapy demonstrated favorable efficacy and acceptable adverse events in the treatment of hematologic malignancies. Well-designed and large sample-sized clinical trials are warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.954345","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T10:59:31Z","timestamp":1672397971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of CD22-specific and CD19\/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Lili","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-022-02802-6","article-title":"Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: A systematic review and network meta-analysis of randomized controlled trials","volume":"13","author":"Luo","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: Recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"Kato","year":"2018","journal-title":"Pediatr Int Off J Japan Pediatr Soc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.3390\/ijms21218000","article-title":"Immunotherapy in hematologic malignancies: Emerging therapies and novel approaches","volume":"21","author":"Noh","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic malignancies: Past, present, and future","volume":"10","author":"Im","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (Car) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: How not to put the cart before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci142030","article-title":"Insight into next-generation car therapeutics: Designing car T cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, cars and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car T-cell therapy in refractory Large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-Cd19 chimeric-Antigen-Receptor-Transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize Cd19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"Kte-X19 car T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (Car T-cells) for cancer immunotherapy - moving target for industry","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory Large b-cell lymphomas (Transcend nhl 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with Cd19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of Cd19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of Cd19 car-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of car-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1183479","article-title":"Medical management of side effects related to car T cell therapy in hematologic malignancies","volume":"9","author":"Namuduri","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T Cells expressing Cd19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-Cd22-Chimeric antigen receptors targeting b-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-021-00465-9","article-title":"A novel full-human Cd22-car T cell therapy with potent activity against Cd22(Low) b-all","volume":"11","author":"Tan","year":"2021","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7","article-title":"Cd22 car T-cell therapy in refractory or relapsed b acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"Cd22-targeted car T cells induce remission in b-all that is naive or resistant to Cd19-targeted car immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1","article-title":"Car T\u2009Cells with dual targeting of Cd19 and Cd22 in pediatric and young adult patients with relapsed or refractory B\u2009Cell acute lymphoblastic leukemia: A phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The prisma 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose Cd19-directed car-T cell therapy in 51 refractory or relapsed b acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci85309","article-title":"Cd19 car-T cells of defined Cd4+:Cd8+ composition in adult b cell all patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized Cd19-targeted chimeric antigen receptor T (Car-T) cells in patients with Relapsed\/Refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/stem.2715","article-title":"Concise review: Emerging principles from the clinical application of chimeric antigen receptor T cell therapies for b cell malignancies","volume":"36","author":"Jain","year":"2018","journal-title":"Stem Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-16-0385","article-title":"Combined anti-vegf and anti-Ctla-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific car-T cells targeting both Cd19 and Cd22 for therapy of adults with relapsed or refractory b cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03279","article-title":"Cd4\/Cd8 T-cell selection affects chimeric antigen receptor (Car) T-cell potency and toxicity: Updated results from a phase I anti-Cd22 car T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160","article-title":"Combination of Cd19 and Cd22 car-T cell therapy in relapsed b-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.3390\/cancers13184582","article-title":"Multiparametric flow cytometry for mrd monitoring in hematologic malignancies: Clinical applications and new challenges","volume":"13","author":"Riva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_320085","article-title":"Car T-cell therapy in hematologic malignancies: Clinical role, toxicity, and unanswered questions","volume":"41","author":"Gill","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the car-T: Risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy195","article-title":"Cost-effective but unaffordable: The CAR-T conundrum","volume":"111","author":"Leech","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2957","article-title":"SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations","volume":"40","author":"Abid","year":"2022","journal-title":"Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01795-3","article-title":"Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients - targeting the target antigen","volume":"57","author":"Uyemura","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T10:59:35Z","timestamp":1672397975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":48,"alternative-id":["10.3389\/fonc.2022.954345"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.954345","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"article-number":"954345"}}